The ongoing debate surrounding pharmaceutical expenditures in the United States has reached a critical juncture with the introduction and subsequent analysis of the Most-Favored-Nation (MFN) drug pricing policy. A comprehensive international modelling study recently published in The Lancet has shed light on the dual-edged nature of this executive initiative. While the policy successfully reduces domestic Medicare spending on brand-name pharmaceuticals by benchmarking U.S. costs against those of comparable high-income economies, it simultaneously introduces significant economic incentives that could destabilize global drug markets. According to researchers from Harvard University, the London School of Economics, and the University of Zurich, the policy threatens to drive up prescription costs outside the United States, delay international drug launches, and encourage pharmaceutical manufacturers to bypass domestic pricing caps through confidential side agreements.
Background Context and Evolution of U.S. Drug Pricing Reform
For decades, residents of the United States have shouldered significantly higher costs for prescription medications than citizens of virtually any other developed nation. Historically, the federal Medicare program—which provides health coverage to approximately 68 million older and disabled Americans—was legally barred from negotiating drug prices directly with pharmaceutical manufacturers. This structural limitation changed marginally with the passage of the 2022 Inflation Reduction Act, which authorized limited direct negotiation for a select group of high-expenditure medications.
However, the Trump administration sought a more sweeping structural transformation through the implementation of Most-Favored-Nation pricing frameworks. Under this administrative directive, what Medicare pays for brand-name medicines is directly tied to the lowest prices charged in a reference basket of high-income countries, adjusted for purchasing power parity. The policy operates primarily through two distinct pricing models: GLOBE, which governs pharmaceuticals administered within hospital and clinical settings, and GUARD, which manages drugs dispensed through retail and specialty pharmacies. Under current parameters, these models randomly select 25 percent of Medicare beneficiaries to be covered over a designated five-year rollout period.
Detailed Financial Analysis and Projected Savings
To measure the financial viability and market consequences of the MFN policy, the multi-university research team analyzed 195 patented medications. Together, these therapies account for a staggering $87.9 billion in annual Medicare expenditures. The study compared current domestic outlays against pricing data from 19 referenced countries, including nations such as South Korea, Norway, and Australia, which frequently serve as international pricing benchmarks. The analysis revealed that the lowest international benchmark price for these medications was, on average, 71 percent lower than the rates paid by Medicare.
When modeling the outcomes without regulatory exemptions, researchers estimated that the initial implementation phase would yield substantial savings for the federal government. Specifically, Medicare could save $5.2 billion, representing a 16 percent reduction under the GLOBE model, and $6.4 billion, or an 18 percent reduction, under the GUARD framework. Furthermore, if the administration expands the MFN parameters to encompass all Medicare beneficiaries rather than the initial 25 percent sample, projected savings scale dramatically to $21 billion for clinical drugs and $25.5 billion for pharmacy-dispensed medications.
The Threat of Confidential Side Deals and Regulatory Loopholes
Despite the apparent magnitude of these potential savings, the study underscores substantial vulnerabilities that threaten to undermine the policy’s efficacy. Most notably, the prevalence of confidential agreements between pharmaceutical manufacturers and the federal government represents a major loophole. When drugmakers strike side deals that are subsequently excluded from public MFN benchmarks, the true financial impact of the policy is heavily diluted.
The researchers estimated that for the initial cohort of 17 manufacturers that had announced private agreements with the administration at the time of the study, projected government savings would plummet by 71 percent. Consequently, rather than realizing the initial double-digit percentage reductions, actual net savings for Medicare could shrink to a modest 4 to 6 percent. Industry analysts note that while the MFN framework provides a strong rhetorical tool for cost containment, the mechanics of confidential rebates and side negotiations allow major pharmaceutical firms to largely preserve their profit margins while appearing to comply with federal mandates.
Global Market Implications and International Reactions
Perhaps the most alarming projection outlined in the Lancet analysis involves the policy’s international spillover effects. Because the U.S. market represents such a colossal share of global pharmaceutical revenue, enforcing MFN-based price caps fundamentally alters the global economic calculus for drug developers.
For approximately 75 percent of the medicines examined in the study, the projected Medicare savings resulting from the U.S. price reduction would be nearly four times larger than the drug’s total annual sales revenue within the specific foreign country used as the pricing benchmark. In practical terms, this means that maintaining low prices in smaller international markets would cause manufacturers to forfeit vast sums in U.S. revenue under the MFN linking mechanism. Consequently, pharmaceutical companies face an acute financial incentive to abandon lower-priced markets, pressure foreign governments to raise domestic price caps, or delay the introduction of new therapies outside the United States.
International regulatory bodies and healthcare systems have already begun registering the shockwaves of these policy shifts. In March 2026, Tokyo-based pharmaceutical giant Astellas Pharma successfully negotiated higher drug prices within Japan, explicitly arguing that domestic pricing structures could adversely influence its valuations under the U.S. MFN framework. Similarly, market disruptions have surfaced in Europe, including the high-profile withdrawal of a vital cholesterol-lowering medication in Denmark, which policy analysts have linked to shifting global pricing pressures and emerging trade friction.
Expert Perspectives and Policy Dilemmas
Dr. Thomas Hwang, lead author of the study and a researcher at Brigham and Women’s Hospital and Harvard Medical School, emphasized the mounting strain placed on foreign healthcare systems. Referenced countries spanning from Germany and Japan to Australia are experiencing immense pressure from both the U.S. administration and multinational pharmaceutical lobbies to elevate domestic medicine spending. However, this pressure collides with the reality that other developed nations operate under strict budgetary constraints with very little fiscal room to absorb sudden price inflation.
Echoing these concerns, Dr. Kerstin Vokinger of ETH Zurich and the University of Zurich warned that domestic U.S. pricing maneuvers carry profound implications for global health equity. Vokinger noted that policymakers must take proactive measures to ensure that life-saving therapeutic innovations are not withheld or delayed in international markets as a direct consequence of American regulatory restructuring.
Meanwhile, Dr. Aaron Kesselheim, a co-author of the study from Harvard Medical School, acknowledged that while the MFN models were designed to rectify historical disparities in what Americans pay for healthcare, their implementation remains constrained by legal challenges, structural exemptions, and the complex realities of multinational trade agreements.
Looking Forward: Unresolved Questions in Pharmaceutical Governance
As the debate surrounding the Most-Favored-Nation policy continues to evolve, policymakers and healthcare economists face a persistent dilemma. The initiative undeniably provides a mechanism to curb runaway domestic healthcare spending and deliver short-term fiscal relief to the U.S. federal budget. However, the systemic consequences—ranging from strained diplomatic and trade relations with key pharmaceutical-producing allies to reduced drug availability and higher consumer costs abroad—suggest that unilateral domestic pricing policies cannot operate in a vacuum.
Future regulatory adjustments will likely need to balance the imperative of domestic affordability with robust international cooperation, ensuring that efforts to lower American prescription drug expenditures do not inadvertently destabilize the delicate ecosystem of global pharmaceutical research, development, and distribution.
